149 related articles for article (PubMed ID: 19372702)
1. Towards a novel vaccine against human cytomegalovirus based on a chimeric Ad5F35 adenovirus vector expressing the immunodominant antigenic domain 1 epitope.
Zhao P; Ma D; Yan S; Shao N; Zhang J; Bi Z; Dai J; Ji M; Ji C
Intervirology; 2009; 52(1):35-42. PubMed ID: 19372702
[TBL] [Abstract][Full Text] [Related]
2. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
Schrader JW; McLean GR
Immunol Lett; 2007 Sep; 112(1):58-60. PubMed ID: 17714794
[TBL] [Abstract][Full Text] [Related]
3. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.
Axelsson F; Adler SP; Lamarre A; Ohlin M
Vaccine; 2007 Dec; 26(1):41-6. PubMed ID: 18063447
[TBL] [Abstract][Full Text] [Related]
4. [Construction and transfection of eucaryotic expression recombinant vector containing truncated region of UL83 gene of human cytomegalovirus and it's sheltered effect as DNA vaccine].
Gao RB; Li YQ; Wang ML
Wei Sheng Wu Xue Bao; 2006 Jun; 46(3):451-5. PubMed ID: 16933619
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates.
Shen S; Wang S; Britt WJ; Lu S
Vaccine; 2007 Apr; 25(17):3319-27. PubMed ID: 17287056
[TBL] [Abstract][Full Text] [Related]
6. Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.
Britt WJ; Jarvis MA; Drummond DD; Mach M
J Virol; 2005 Apr; 79(7):4066-79. PubMed ID: 15767408
[TBL] [Abstract][Full Text] [Related]
7. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
8. Multiple alternating immunizations with DNA vaccine and replication incompetent adenovirus expressing gB of pseudorabies virus protect animals against lethal virus challenge.
Kim SJ; Kim HK; Han YW; Aleyas AG; George JA; Yoon HA; Yoo DJ; Kim K; Eo SK
J Microbiol Biotechnol; 2008 Jul; 18(7):1326-34. PubMed ID: 18667863
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.
Navarro D; Lennette E; Tugizov S; Pereira L
J Med Virol; 1997 Aug; 52(4):451-9. PubMed ID: 9260696
[TBL] [Abstract][Full Text] [Related]
10. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
[TBL] [Abstract][Full Text] [Related]
11. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
12. Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides.
Ulivieri C; Citro A; Ivaldi F; Mascolo D; Ghittoni R; Fanigliulo D; Manca F; Baldari CT; Li Pira G; Del Pozzo G
Immunol Lett; 2008 Aug; 119(1-2):62-70. PubMed ID: 18538862
[TBL] [Abstract][Full Text] [Related]
13. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures.
Schoppel K; Hassfurther E; Britt W; Ohlin M; Borrebaeck CA; Mach M
Virology; 1996 Feb; 216(1):133-45. PubMed ID: 8614980
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
[TBL] [Abstract][Full Text] [Related]
15. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus.
Zhong J; Rist M; Cooper L; Smith C; Khanna R
PLoS One; 2008 Sep; 3(9):e3256. PubMed ID: 18806877
[TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity.
Shanley JD; Wu CA
Vaccine; 2005 Jan; 23(8):996-1003. PubMed ID: 15620472
[TBL] [Abstract][Full Text] [Related]
17. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients.
Marshall GS; Li M; Stout GG; Louthan MV; Duliège AM; Burke RL; Hunt LA
Viral Immunol; 2000; 13(3):329-41. PubMed ID: 11016597
[TBL] [Abstract][Full Text] [Related]
19. [Construction of a recombinant adenoviral vector expressing human endostatin].
Yuan AQ; He YL; Yang F; Liu MB
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1769-71. PubMed ID: 17259117
[TBL] [Abstract][Full Text] [Related]
20. Vaccine strategies against human cytomegalovirus infection.
Zhong J; Khanna R
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):449-59. PubMed ID: 17547509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
